Advertisement
Organisation › Details
bioMérieux S.A. (Euronext: BIM)
A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached €1.111 billion with 84% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479). Other information can be found at www.biomerieux.com. *
Start | 1999-09-09 existent | |
Group | Mérieux (Group) | |
Industry | BIOTECH | |
Person | Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology) | |
Person 2 | Bélingard, Jean-Luc (Mérieux 201101– Président Directeur Général before Ipsen CEO + Pierre Fabre + Roche Diagnostics) | |
Region | Marcy-l’Étoile, Rhône | |
Country | France | |
City | 69280 Marcy l’Étoile | |
Tel | +33-4-7887-2000 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | H: 10,001 to 50,00 (2017-12-31) |
Currency | EUR | |
Annual sales | 2,288,200,000 (sales, net, consolidated (2017) 2017-12-31) | |
Profit | 237,600,000 (2017-12-31) | |
Cash | 312,100,000 (2017-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Mérieux (Group)
- [1] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
- [2] Oxford Biomedica plc. (9/20/23). "Press Release: Oxford Biomedica and Institut Mérieux Enter into Exclusive Negotiations with Respect to the Proposed Acquisition by Oxford Biomedica of ABL Europe". Oxford....
- [3] Transgene S.A.. (5/5/23). "Press Release: Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio". Strasbourg....
- [4] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
- [5] ABL Biomanufacutring. (3/27/23). "Press Release: ABL Appoints Stéphanie Colloud as General Manager and Chief Operating Officer to Lead European Activities". Lyon....
- [6] InDevR, Inc.. (1/17/23). "Press Release: InDevR Raises $9 Million in Series B Financing and Partners with bioMérieux". Boulder, CO....
- [7] Transgene S.A.. (12/15/22). "Press Release: Transgene Announces Upcoming Investor Meetings". Strasbourg....
- [8] Mablink Bioscience S.A.S.. (10/14/22). "Press Release: Mablink Bioscience Announces a €31 Million Series A Funding Round Led by Sofinnova Partners and Mérieux Equity Partners". Lyon....
- [9] Weezion S.A.S.. (6/1/22). "Press Release: Weezion, a French MedTech Start-up, Announces Capital Investment from bioMérieux". Lyon....
- [10] bioMérieux S.A.. (3/18/22). "Press Release: bioMérieux Receives FDA 510(k) Clearance for Its VITEK MS PRIME New MALDI-TOF Mass Spectrometry Identification System". Marcy l’Étoile....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top